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Background: Serotonergic system dysfunction has been implicated in posttraumatic stress disorder (PTSD). Genetic
polymorphisms associated with serotonin signaling may predict differences in brain circuitry involved in emotion
processing and deficits associated with PTSD. In healthy individuals, common functional polymorphisms in the
serotonin transporter gene (SLC6A4) have been shown to modulate amygdala and prefrontal cortex (PFC) activity
in response to salient emotional stimuli. Similar patterns of differential neural responses to emotional stimuli have
been demonstrated in PTSD but genetic factors influencing these activations have yet to be examined.
Methods: We investigated whether SLC6A4 promoter polymorphisms (5-HTTLPR, rs25531) and several downstream
single nucleotide polymorphisms (SNPs) modulated activity of brain regions involved in the cognitive control of
emotion in post-9/11 veterans with PTSD. We used functional MRI to examine neural activity in a PTSD group (n =
22) and a trauma-exposed control group (n = 20) in response to trauma-related images presented as task-irrelevant
distractors during the active maintenance period of a delayed-response working memory task. Regions of interest
were derived by contrasting activation for the most distracting and least distracting conditions across participants.
Results: In patients with PTSD, when compared to trauma-exposed controls, rs16965628 (associated with serotonin
transporter gene expression) modulated task-related ventrolateral PFC activation and 5-HTTLPR tended to modulate
left amygdala activation. Subsequent to combat-related trauma, these SLC6A4 polymorphisms may bias serotonin
signaling and the neural circuitry mediating cognitive control of emotion in patients with PTSD.
Conclusions: The SLC6A4 SNP rs16965628 and 5-HTTLPR are associated with a bias in neural responses to
traumatic reminders and cognitive control of emotions in patients with PTSD. Functional MRI may help identify
intermediate phenotypes and dimensions of PTSD that clarify the functional link between genes and disease
phenotype, and also highlight features of PTSD that show more proximal influence of susceptibility genes
compared to current clinical categorizations.
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Imaging genetics has been used to identify the role of
genes in modulating brain differences associated with
behavioral and cognitive symptom features in a number
of psychiatric disorders [1,2], including mood disorders
[3], anxiety disorders [4-6], and schizophrenia [7].
Whereas imaging genetics has generally relied on
exploration of candidate gene effects, gene discovery has
generally been accomplished through genome wide asso-
ciation studies (GWAS). Recently, however, imaging
genetics has become a fruitful avenue for gene discovery
or identifying allelic variants of known candidate genes
that are associated with brain disorders such as schizo-
phrenia and Alzheimer’s disease [8,9]. Neuroimaging
studies have revealed important structural and func-
tional brain abnormalities in neuropsychiatric disorders,
and mounting evidence suggests that genetic variability
is reflected in brain activity as observed with neuroima-
ging methods [10].
Although imaging genetics studies in PTSD are lacking,
a few studies have examined candidate gene associations
with the behavioral phenotype of PTSD [11-17]. These
studies are consistent with evidence of a genetically
mediated vulnerability to PTSD in the context of trau-
matic stress exposure. Individuals with a family history of
PTSD have a 3 to 5 fold relative risk of developing PTSD
[18-20], and twin studies suggest the heritability for
PTSD is over 30% [21,22]. Growing evidence suggests
that the serotonin transporter gene linked polymorphic
region (5-HTTLPR) is associated with risk for PTSD. The
frequency of 5-HTTLPR short homozygotes was greater
in PTSD patients relative to healthy control subjects who
were not recruited for the presence of trauma exposure
[11]. Recent studies have begun to examine the role of
gene-environment interplay in PTSD risk mechanisms
[23]. In a study of highly traumatized Rwandan refugees,
5-HTTLPR genotype predicted PTSD risk; individuals
homozygous for the short allele were at high risk for
developing PTSD regardless of levels of trauma exposure,
whereas the other genotypes exhibited a dose-response
relationship of the number of lifetime trauma events with
risk for PTSD [14]. In hurricane survivors, the expression
levels of the serotonin transporter gene were associated
with PTSD, but only in the setting of high exposure to
stress and low social support [12]. A recent study showed
the 5-HTTLPR genotype alone did not predict PTSD, but
rather interacted with childhood adversity and adult trau-
matic events to increase the risk of PTSD, particularly
with high levels of exposure to both trauma types [15].
However, the “common disease common variants”
hypothesis suggests multiple genes and gene variants
(common variants) are likely to influence risk for PTSD
(common disease) [24], and therefore these initial intri-
guing associations are likely only a small part of the
story. The effect of individual gene variants may be more
precisely characterized by examining phenotypes closer
to the biological activity of the gene in the context of
PTSD [25,26]. Imaging genetics is one approach that is
gaining interest in the assessment of the genetic modula-
tion of neural activity associated with specific behavioral
phenotypes [1,26,27]. For instance, variants of the 5-
HTTLPR gene have been associated with differential acti-
vation in the amygdala [28-35], a region of the brain
associated with fear learning [36] and shown to be hyper-
active during emotion processing in PTSD [37,38]. For
example, patients with PTSD exhibited greater activation
for trauma-relevant pictures in the amygdala and ventro-
lateral prefrontal cortex( P F C ) ,w h e nc o m p a r e dt o
trauma-exposed controls [37,39-41]. Furthermore,
SLC6A4 variants have been linked to alterations in pre-
frontal activation during cognitive processing [28]. The
inferior PFC, particularly the ventrolateral PFC, plays an
important role in the cognitive processing of emotionally
salient information [42-47]. Genetic mechanisms appear
to influence serotonergic pathways related to human fear
conditioning [48]. Fear conditioning models have been
applied to prominent PTSD symptoms (e.g., hypervigi-
lance and exaggerated fear response to cues of the trau-
matic event) and proposed to inform neuroimaging and
genetics investigations of PTSD (reviewed in [49,50]).
Our goal was to investigate the link between common
variants of the serotonin transporter gene (including 5-
HTTLPR) and known functional brain differences in
PTSD. Our hypotheses followed from the previously
demonstrated role of this candidate gene in modulating
neural activity in emotion processing regions [51]
coupled with the findings of genetic influences in PTSD
[11-14] and other anxiety disorders [52,53].
Until recently, the 5-HTTLPR was analyzed as function-
ally biallelic with Long (L, 16 repeats) and Short (S, 14
repeats) alleles where the S allele leads to lower expression
of mRNA and reduced serotonin transporter in mem-
branes. More recently a functionally triallelic classification
includes an A/G single nucleotide polymorphism (SNP),
rs25531, that is observed predominantly within the L allele
(LA and LG alleles)[54,55]. In light of reported effects of
intragenic SNPs on transcriptional activity, it is important
to evaluate not only these promoter polymorphisms, but
common sequence variation across the entire gene for
association with altered brain function in PTSD. We pre-
dicted that variation in the following functional poly-
morphisms would modulate neural activity in the
amygdala and the ventrolateral PFC in patients with
PTSD: 5-HTTLPR/rs25531 previously associated with
severity of PTSD, rs140701 previously associated with
panic disorder [52], and rs16965628 previously associated
with obsessive compulsive disorder (OCD) in haplotype
analysis [53] and recently reported to exert the greatest
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transporter gene expression in human cell lines [56].
Across all variants, we hypothesized that those previously
associated with PTSD or other anxiety disorders and/or a
relative decrease in 5-HTT expression would predict
increased amygdala and ventrolateral PFC activation
[37,40,41,57,58]. Moreover, consistent with GxE models
we hypothesized that any genotype-related differences in
brain function would be most pronounced in patients with
PTSD.
In a previously reported fMRI study of PTSD [37], we
assessed neural activation in a working memory task
during the delay interval between encoding and retrieval
when active maintenance of visual information was dis-
rupted by the presentation of trauma-related distractors.
The present study examined the role of serotonin trans-
porter gene variants on PTSD patients and trauma-
exposed controls whose regional brain activity we pre-
viously reported [37].
Subjects and Methods
Here, we provide details of genotyping and statistical
analyses of candidate gene effects on fMRI data.
Detailed information about participants, cognitive chal-
lenge task, and fMRI analyses are previously published
[37] and repeated here in summary form.
Participants
Participants included a PTSD group (n = 22) and a
trauma-exposed control group (n = 20) with comparable
levels of combat exposure measured by the Combat
Exposure Scale [t(40) = 1.2, p = 0.2]. Subjects provided
written informed consent to participate in procedures
approved by the Institutional Review Boards at Duke
University and Durham VA Medical Center. The 42
subjects who underwent fMRI assessment were geno-
typed as part of a parent sample of 387 registry subjects.
Subjects completed a screening battery to assess comor-
bid neuropsychiatric disorders (see Table 1). The David-
son Trauma Scale (DTS) was administered just prior to
scanning to assess PTSD symptom severity (Davidson et
al. 1997). Lacking a diagnostic interview in these sub-
jects, a DTS cutoff score of 32, previously shown by us
to have high diagnostic efficiency (0.94) in the post-9/11
military cohort [59], was used to divide the participants
into a PTSD group with mean DTS (SD) = 74.4 (18.8)
and Control group with mean DTS = 10.2 (8.8). The
use of two diagnostic groups in favor of a correlational
approach was further influenced by the presence of a
strong bimodal distribution of DTS scores.
Genotyping Methods
SNPs for SLC6A4 (see Figure 1) were chosen using
phase II Caucasian (CEU) and Yoruban (YRI) genotype
data of the International HapMap Project [60]. A com-
bined list of tagging SNPs was selected with LD-Select
Version 1.0 [61] and MultiPop-TagSelect Version 1.1
software [62], with r
2 = 0.3 and minor allele frequency
(MAF) > 0.1. Coding SNPs with MAF > 0.1 were forced
into the list. SNPs were genotyped using TaqMan
® SNP
Genotyping Assays (Applied Biosystems Inc.). The 5-
HTTLPR/rs25531 polymorphism was genotyped in two
parts. After PCR amplification, 1 μl of product was used
for fragment analysis of the short (S), long (L), and
extra long (XL) alleles of the insertion/deletion poly-
morphism (484, 528, and 594 bp, respectively; ABI 3730
DNA Analyzer Capillary Array; GeneMapper
® Software,
version 4.0, Applied Biosystems Inc.). The remaining
product was digested by restriction enzyme HpaII (New
England BioLabs Inc) to determine the LG,S( S A)a n d
LA alleles (174, 297 and 340 bp, respectively). Call rates
for all polymorphisms analyzed in this study were ≥95%.
Stimuli and Working Memory Task Design
During the fMRI scan, subjects performed a working
memory task with combat-related and control distrac-
tors. Each trial consisted of an encoding phase, a delay
period with trauma-related and non-trauma-unrelated
visual distractor scenes and a retrieval phase for an
epoch duration of 29 s with 12.5 s between epochs. The
encoding phase consisted of three similar faces pre-
sented for 3.5 s, which subjects encoded into working
memory and maintained for 11.5 s. The visual distrac-
tors consisted of two consecutively displayed (i) combat
scenes, (ii) non-combat scenes, or (iii) digitally
scrambled pictures (control condition) presented for 3 s
each. Combat and non-combat scenes were adapted
from a superset of images [58] for which combat scenes
had more negative emotional valence than non-combat
scenes. During the retrieval phase, a single-face was pre-
sented requiring a button response to indicate its pre-
sence (old) or absence (new) during encoding. Subjects
viewed 40 trials per stimulus type.
Imaging Protocol
Images were acquired on a 4T General Electric SIGNA
MRI scanner. Full-brain coverage was obtained with 34
interleaved axial functional slices (TR/TE/flip = 2000
ms/31 ms/60°; FOV = 240 mm; 3.75 × 3.75 × 3.8 mm
voxels; interslice skip = 0) using an inverse-spiral pulse
sequence. High-resolution 3D spin-echo co-planar struc-
tural images were acquired in 68 axial slices (TR/TE/flip
=1 2 . 2m s / 5 . 3m s / 2 0 ° ,v o x e ls i z e=1×1×1 . 9m m ,
FOV = 240 mm, interslice skip = 0).
Analysis of Functional MRI Data
Preprocessing of individual functional data sets was per-
formed with FSL version 3.3.5 [Oxford Centre for
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(FMRIB), Oxford University, U.K.][63]. All registrations
were carried out using FMRIB Linear Image Registration
Tool (FLIRT) for linear (affine with 12 degrees of free-
dom) registration [64]. Following preprocessing, subse-
quent data analyses used whole brain voxel-wise and
region of interest (ROI) approaches to compare brain
activity associated with the contrasts of interest (e.g.,
combat vs. non-combat conditions). For individual sub-
ject analyses, the fMRI signal was selectively averaged in
each subject as a function of trial type (i.e., combat,
non-combat, and scrambled) and image volume (TR)
within the trial epoch (two image volumes preceding
epoch onset and 14 image volumes following epoch
onset), and compared for the contrasts of interest using
pairwise t-statistics. Individual subject analyses produced
whole-brain average and activation t-maps for each con-
dition, contrast of interest, and sub-epochs (encoding,
maintenance, and retrieval). Data for sub-epochal con-
trast maps was extracted from the overall time course
by averaging image volumes representing maximal
change relative to the pre-memorandum onset baseline.
Determination of Functional Regions of Interest
Functional regions of interest (ROIs) were defined by
voxels showing the maximum effects during the active
maintenance period for the contrasts of interest (see
Figure 2). Specifically, contrast activation maps between
Table 1 Demographic and Clinical Characteristics of Subject Sample
1
Characteristic Control n = 20 PTSD n = 22 Group Comparison
Age (years) [SD] 37.6 [11.0] 30.8 [8.8] t(40) = 2.2, p < 0.05
Gender, No.(%) of females 7 (35.0) 13 (59.1) c
2(1) = .29, p > 0.5
Handedness, No.(%) right-handed 17 (85.0) 19 (86.4) c
2(2) = 0.68, p > 0.7
Race, No.(%) of Caucasian subjects 8 (40.0) 12 (54.5) c
2(2) = 2.1, p > 0.3
Education (years) [SD] 13.9 [2.8] 13.3 [1.8] t(40) = 0.8, p > 0.4
Davidson Trauma Scale [SD] 10.2 [8.8] 74.4 [18.8] t(40) = 13.9, p < 0.001
Combat Exposure Scale [SD] 8.6 [11.0] 12.6 [10.3] t(40) = 1.2, p > 0.2
Beck Depression Inventory [SD] 7.1 [6.1] 20.8 [9.0] t(40) = 5.7, p < 0.001
Alcohol Use Disorders Identification Test [SD] 2.6 [3.2] 6.1 [6.3] t(40) = 2.6, p < 0.05
Drug Abuse Screening Test, [SD] 0.4 [0.8] 2.1 [2.5] t(40) = 2.9, p < 0.01
Antidepressant Medication, No. (%) prescribed
2 1 (5.0) 8 (36.4) c
2(1) = 6.1, p < 0.01
Antidepressant Dosage equivalents [SD]
2 0.9 [4.3] 14.5 [19.9] t(40) = 3.0, p < .005
1 Data values represent means except where indicated otherwise.
2 Antidepressant medications taken were either selective serotonin reuptake inhibitors (SSRIs) or mirtazipine. Antidepressant dosage equivalents are listed in
Table 3.
Figure 1 Exon/intron structure and location of SNPs genotyped for SLC6A4. The SNP rs16965628 previously associated with obsessive
compulsive disorder (OCD) exerts the greatest relative effect of common SLC6A4 variants on serotonin transporter gene expression in human
cell lines.
Morey et al. BMC Psychiatry 2011, 11:76
http://www.biomedcentral.com/1471-244X/11/76
Page 4 of 13the most vs. least distracting conditions (combat >
scrambled distractors) showed strong activation in the
amygdala, ventrolateral PFC, and fusiform gyrus, but the
inverse contrast (scrambled > combat distractors)
showed strong deactivations (signal activity below the
inter-trial baseline) in the dorsolateral PFC (dlPFC) and
lateral parietal cortex (LPC). Given our a priori hypoth-
eses derived from non-clinical participants [45], we used
an intensity threshold of t >3 . 0( p < 0.002) and an
extent threshold of 10 contiguous voxels solely for the
purpose of defining functional ROIs.
Statistical Analyses
Analysis of working memory performance, as measured
by detectability scores (d-prime = |Z(hit rate) - Z(false
alarm rate)|) and defined by standard signal detection
theory, used general linear modeling (GLM) to deter-
mine the influence of genotype. The dependent variable
was repeated-measures d-prime scores for distractor-
type (combat distractor, non-combat distractor scene).
The factors and covariates were identical to fMRI data
analysis described below.
The main hypothesis was tested by interrogating the
genetic modulation of neural activity in PTSD relative
to trauma-exposed control subjects. The dependent
measure in the GLM was the difference in mean activa-
tion (percent signal change) between combat distractors
and non-combat distractor scenes during the active
maintenance phase of the working memory task in the
functional ROIs. Factors were diagnosis (2 levels; PTSD,
control) and genotype with the number of levels specific
to the genetic polymorphism being tested. For example,
3 levels associated with transcriptional efficiency were
used for triallelic 5-HTTLPR (low, reference, high) and
2 levels for rs16965628 (CG, GG). The number of levels
per genotype factor are listed in Table 2 for each poly-
morphism. Higher depression scores and antidepressant
medication usage in the PTSD group prompted the
introduction of two covariates, score on the Beck
Depression Inventory (BDI; [65]), and antidepressant
medication dosage equivalents (see Table 3). There were
no significant differences in trauma exposure as mea-
sured by the Combat Exposure Scale ([66]; (see Table
1). Despite no significant differences in the means and
variances of ROI activation between African American
and European American subjects (see Table 4, race was
included as a covariate to account for the considerable
differences in allele frequencies between individuals of
African and European ancestry. Finally, to assess the
possibility of stratification due to race we carried out a
race based analysis for the significant results. Despite
the low sample size in the resulting cells, main effect of
genotype, then an effect of genotype within diagnostic
groups, was assessed to confirm a pattern in the same
direction as the overall finding.
Given the concern of statistical power with a small
sample size, we considered only polymorphisms that
had a minimum of six subjects per genotype, or five
subjects for polymorphisms with ap r i o r ihypotheses.
Accordingly for biallelic 5-HTTLPR, the genotypes were
categorized as S allele carriers (SS, SL) or non-S allele
carriers (LL) to enable analysis of 5 subjects per geno-
type category. For triallelic 5-HTTLPR, the low expres-
sing group included genotypes LGLG,S L G,S S ,t h e
reference group included genotypes SLA and LGLA gen-
otypes, and the high expressing genotype (LALA)w a s
not included due to inadequate sample (see Table 2).
Sample size information on the remaining polymorph-
isms is provided in Table 2. Based on this restriction,
only nine (8 SNPs + 1 promoter) of the 14 polymorph-
isms assayed on SLC6A4 were considered in the final
analysis. All polymorphisms were tested for Hardy-
Weinberg disequilibrium in the PTSD and control
groups and by race in the parent sample and separately
in the present sample. The SNPs that significantly
modulated neural activity in hypothesized ROIs were
assessed for LD with the 5-HTTLPR.
Adjustments for multiple comparisons were made
with the Nyholt correction for testing multiple SNPs in
linkage disequilibrium (LD) based on the spectral
decomposition of matrices of pairwise LD between
SNPs [67]. The Nyholt correction reduced the number
of effective comparisons from eight to six. The 5-





6 t = 3






Figure 2 Definition of functional regions of interest.F i v e
functional ROIs were defined from dissociable dorsal-ventral patterns
of activity observed during the working memory delay period (in the
presence of distractors in 42 subjects). The most disruptive effect on
activity during the delay period in a set of dorsal brain regions
associated with working memory (blue blobs) including the
dorsolateral PFC (dlPFC) and the lateral parietal cortex (LPC). Combat
distracters produced the most enhancing effect on activity on ventral
brain regions associated with emotion processing (red blobs)
including the amygdala, ventrolateral PFC, and fusiform gyrus. The
activation maps show direct contrasts between the most versus least
distracting conditions, combat > scrambled (red) and scrambled >
combat (blue), with colored gradient bars indicating t values.
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Page 5 of 13test. Thus, to maintain the Type I error rate at .05 given
a total of 7 effective comparisons (6+1), the p-values
were multiplied by 7. The reported p-values are from
the omnibus F-test for a GLM that includes genotype,
PTSD status and genotype*diagnosis product (interac-
tion) term. Only when the corrected p-value (pcorr)f o r
the omnibus F-test was significant (pcorr < .05), did we
report specific p-values for main effect of genotype and
the interaction genotype*diagnosis. The main effects for
diagnosis were reported in detail previously [37].
Results
Working memory performance
Working memory performance was measured using
detectability scores (d-prime or D’)a n dt e s t e dw i t ha
GLM. No significant effects were found for SLC6A4
polymorphisms rs16965628 [F(1,36) = .83, p = .37], trial-
lelic 5-HTTLPR [F(1,34) = .61, p = .44], or rs140701 [F
(1,34) = 2.2, p = .15]. Behavioral results for the remain-
ing polymorphisms are summarized in Table 5.
Table 2 Allele and genotype frequencies for SLC6A4 polymorphisms














rs9903602 GG; GT; TT 6, 9, 27 2,4; 3,6; 12,15 .178 7.7 .005 exclude
rs9896947 CC, CT, TT 28, 14, 0 13,15; 7,7; 0,0 .833 1.68 .20 CC,CT
rs9303628 AA; AG;GG 6, 16, 20 3,3; 10,6; 7,13 .333 .86 .35 AG, GG
rs7212502 AA; AG; GG 38, 4, 0 20,18; 2,2; 0,0 .952 .105 .75 exclude
rs4583306 AA; AG; GG 17, 18, 7 10,7; 7,11; 3,4 .619 .350 .55 AA, AG
rs4251417 CC; CT; TT 36, 6, 0 18,18; 2,4; 0,0 .929 .25 .68 exclude
rs3813034 AA; AC; CC 14, 16, 12 9,5; 7,9; 4,8 .274 2.34 .13 exclude
rs2020936 AA, AG, GG 23, 17, 2 9,14; 10,7; 1,1 .750 .265 .61 AA, AG
rs16965628
3 CC; CG; GG 0, 15, 27 0,0; 8,7; 13,14 .179 1.98 .18 CG, GG
rs16965623 AA; AG; GG 37, 5, 0 18,19; 2,3; 0,0 .940 .170 .68 exclude
rs140701
3 CC; CT; TT 11, 21, 10 7,4; 8,13; 5,6 .512 .000 .99 CT, TT
rs12150214 CC; CG; GG 3, 17, 22 1,2; 11,16; 8,14 .274 .013 .91 CG, GG











SS; SL; LL 10, 20, 12 3,7; 12,8; 5,7 .476 .087 .77 S carriers, LL
3 polymorphisms with a priori hypothesis
4 group sizes are reported the number of control and PTSD subjects for each of three genotypes, listed in the order [homozygous, heterozygous, homozygous]
and secondarily alphabetical order of coding bases (A, C, G, T).
Abbreviations: Hardy-Weinberg Equilibrium (HWE)
Table 3 Medication dose and dose equivalents
Subject Group Medication(s) Dose Equivalents
7
1 Control mirtazipine 15 mg 20
2 PTSD sertraline 50 mg, fluoxetine 10
mg
30
3 PTSD paroxetine 40 40
4 PTSD sertraline 100 40
5 PTSD mirtazipine 15 mg, citalopram
10
30
6 PTSD mirtazipine 15 20
7 PTSD mirtazipine 15 mg, sertraline
100
60
8 PTSD sertraline 50 mg 20
9 PTSD mirtazipine 30 40
7 Antidepressant medication dosage equivalents based on the following dose
equivalence formula: 20 mg citalopram = 50 mg sertraline = 5 mg
escitalopram = 50 mg fluvoxamine = 20 mg paroxetine = 20 mg fluoxetine =
15 mg mirtazipine.
Table 4 Effect of race on mean ROI activation
main effect race, race * genotype (p-value;
uncorrected)
Polymorphism vlPFC amygdala fusiform gyrus dlPFC LPC
rs16965628 .13, .34 .26, .02 .39, .45 .55, .57 .53, .63
rs9896947 .25, .64 .32, .14 .07, .05 .33, .24 .30, .27
rs9303628 .44, .84 .91, .94 .35, .81 .55, .58 .69, .22
rs4583306 .01, .13 .12, .25 .45, .47 .42, .13 .15, .21
rs2020936 .30, .75 .91, .06 .16, .93 .69, .15 .52, .94
rs140701 .22, .98 .14, .25 .38, .87 .33, .03 .42, .32
rs12150214 .32, .80 .67, .17 .46, .88 .59, .30 .44, .99
rs11080122 .54, .81 .98, .32 .19, .68 .71, .19 .68, .77
triallelic 5HTTLPR .13, .66 .67, .21 .34, .66 .54, .38 .96, .05
biallelic 5HTTLPR .15, .46 .75, .84 .51, .81 .88, .26 .74, .04
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None of the genotypic variants showed evidence of
Hardy-Weinberg disequilibrium in the present sample
(see Table 2) or across race or diagnostic group in the
parent sample of 387 subjects (data not shown). We
found the serotonin transporter gene SNP rs16965628
significantly modulated activation of the ventrolateral
PFC in the PTSD group, but not the non-PTSD group
(see Figure 3). Specifically, ANCOVA modeling showed
a significant effect of ventrolateral PFC activation during
presentation of combat-distractors relative to non-com-
bat distractor scenes in the working memory delay per-
iod [F(5,36) = 3.9, pcorr < .05]. A significant
diagnosis*genotype interaction was found in the ventro-
lateral PFC [F(1,36) = 7.8, pcorr < .05] with planned
comparisons revealing greater activation for GG genoty-
pic variants with PTSD than trauma-exposed control
participants [t(13) = 3.8, p = .0004] whereas no differ-
ence was observed between PTSD and trauma-exposed
control participants with the CG genotype [t(25) = .05,
p = .9]. The distribution of rs16965628 alleles were
found to be non-independent with those of the 5-
HTTLPR [c
2( 2 )=8 . 2 ,p<. 0 2 ] .T h i sS N Pw a sa n a l y z e d
separately for each race. In the African American group,
rs16965628 significantly modulated activation of the
ventrolateral PFC in the PTSD group, but not the non-
PTSD group [F(5,22) = 10.9, p < .0001]. Only a weak
trend in this direction was observed in the European
American group [F(5,22) = 1.7, p < .20].
Influence of 5-HTTLPR (biallelic) on the amygdala
was examined in the context of reports showing effects
in the right [30,31] and the left [28] amygdala while
viewing threat-related cues. Our analysis of S allele car-
r i e r sv e r s u sn o n - c a r r i e r s( L L )s h o w e dat r e n df o rl e f t
amygdala [F(6,35) = 3.4, pcorr = .07] activation, but no
association in the right amygdala [F(6,35) = 2.5, pcorr >
.2]. Planned comparisons showed greater left amygdala
activation in the PTSD group than the trauma exposed
control group for S allele carriers [t(28) = 2.2, p < .05]
but no difference between diagnostic groups among par-
ticipants with the LL genotype [t(28) = 0.1, p > .9] Acti-
vation in other ROIs, including ventrolateral PFC,
fusiform gyrus, dorsolateral PFC, and lateral parietal
cortex, did not attain the significance for biallelic 5-
HTTLPR. The other hypothesized polymorphisms such
as rs140701 and triallelic 5-HTTLPR did not attain sig-
nificance for any of the ROIs (see Table 5).
With an insufficient sample of LALA to perform between
group analysis, the effects of LALA on the overall group
(PTSD + trauma-exposed) resulted in 9 subjects in the
LALA group and 33 subjects in the non-LALA group (S and
LG carriers). Significantly greater activation was present
the LALA group in the right amygdala [F(1, 37) = 5.86; p <
.05], left amygdala [F(1, 37) = 5.98; p < .05], and the fusi-
form gyrus [F(1, 37) = 5.02; p < .05]. There were no
between group differences in the ventrolateral PFC, the
dorsolateral PFC, or the lateral parietal cortex.
Table 5 SLC6A4 and PTSD effects on mean ROI activation








rs16965628 .03*, .05*, .03* .89 .57 .22 .45 .99
rs9896947 .19 .99 .44 .99 .24 .99
rs9303628 .60 .25 .10, .18 .24 .99
rs4583306 .40 .64 .54 .78 .93 .99
rs2020936 .88 76 .77 .99 .67 .77
rs140701 .99 .99 .34 .99 .99 .99
rs12150214 .79 .87 .76 .99 .95 .69
rs11080122 .09 .98 .51 .99 .24 .99
triallelic
5HTTLPR




6 .14 .99 .99 .99
5 The p-value(s) are from the omnibus F-test for a general linear model (GLM)
that includes genotype, diagnosis (PTSD status) and genotype*diagnosis
product (interaction) term. Factors include diagnosis (2 levels; PTSD, control)
and genotype with 2 or 3 levels (see Table 2). Covariates are race (African
American or European American), score on the Beck Depression Inventory
(BDI; see Table 1) and antidepressant medication dose equivalents (see Table
3). Significance level was adjusted by multiplying by the number of effective
multiple comparisons (seven) that was calculated with the Nyholt correction.
6 left amygdala (pcorr = .07), right amygdala (pcorr >.2).
Abbreviations: region of interest (ROI), dorsolateral prefrontal cortex (dlPFC),






























Figure 3 SLC6A4 (rs16965628) modulated the ventrolateral PFC
in PTSD. (a) mean activation level in the ventrolateral PFC ROI for
combat vs. non-combat distractors presented during the working
memory delay period was differentially modulated by rs16965628 in
the PTSD group as compared to the trauma-exposed control group.
(b) mean activation in the left amygdala ROI for combat vs. non-
combat distractors presented during the working memory delay
period was differentially modulated by 5-HTTLPR (S allele carrier, LL)
in the PTSD group as compared to the trauma-exposed control
group.
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T h ep r e s e n ts t u d yi n v e s t i g a t e dt h ee f f e c t so fs e r o t o n i n
transporter gene polymorphisms on neural activity asso-
ciated with distraction from goal-directed cognitive pro-
cessing by trauma-relevant cues in patients with PTSD.
Brain activation was assessed during the delay interval
between encoding and retrieval when active maintenance
of information was disrupted by the presentation of
trauma-related visual distractors that were irrelevant to
the working memory task. We found rs16965628, the
nearest tagging SNP downstream (3’) of 5-HTTLPR (see
Figure 1), significantly modulated task-related ventrolat-
eral PFC activation in patients with PTSD while being
distracted by combat compared to non-combat scenes
(see Figure 3). In addition, the 5-HTTLPR showed trend
level modulation of left amygdala activation during the
working memory delay period in S allele carriers with
PTSD (see Figure 3). We did not detect an association
between triallelic 5-HTTLPR and task related neural
activity in PTSD but confirmed greater bilateral amygdala
activation associated with LALA in the overall group.
We found the rs16965628 alleles were significantly
associated with 5-HTTLPR alleles wherein the G allele
of the SNP co-segregated with the S allele of 5-
HTTLPR, which has been implicated in PTSD [11-15].
Interestingly, rs16965628 has been reported to exert the
greatest relative effect amongst common variants on the
level of serotonin transporter gene expression in human
cell lines [56]. Its role was elaborated by assaying allelic
imbalance in cell lines genotyped by the HapMap con-
sortium. These investigators examined 55 SNPs in the
100 kb window around SLC6A4 to assess their influence
on gene transcription. They found that aside from 5-
HTTLPR, two SNPs rs16965828 and rs2020933 that are
located in the first intron of the gene and highly corre-
lated with each other, made the greatest contribution to
the variation in serotonin transporter gene expression
[56]. The present results suggest that rs16965628
accounts for a substantial difference in distractor-related
activation of the ventrolateral PFC between PTSD and
trauma-exposed control groups. The ventrolateral PFC
is known to have an important role in the cognitive
control and processing of emotionally salient informa-
tion [42,43,45,46,68,69]. Previously, we reported greater
activation in the PTSD group compared to the trauma-
exposed control group in ventrolateral PFC during cog-
nitive tasks such as working memory and executive pro-
cessing [37,39,58]. Findings from our previous
investigations [42,45] suggest an engagement of this
region both in general emotion processing and in coping
with emotional distraction. The observed intermediate
phenotype of increased ventrolateral PFC activation dur-
ing the distraction delay period appears to be related to
the GG gentotpye of rs16965628 in patients with PTSD,
which shows both increased emotional reactivity and a
need for greater allocation of resources to maintain
working memory performance in the face of emotional
distraction. The observation of a significant association
of a SLC6A4 SNP and PTSD (an association that has
not previously been reported with a diagnostic pheno-
type) underscores that an intermediate phenotype
approach may be more sensitive and powerful than
behavioral measures given that neural circuitry is more
proximal to gene effects than to behavior. The findings
also highlight the potential value of intermediate pheno-
types identified by imaging genetics for the discovery of
associations between gene variants and disease.
Since rs16965628 has not been described in the ima-
ging genetics literature, we consider our results in the
context of closely associated 5HTTLPR [56]. A limited
number of studies have examined the role of 5HTTLPR
on the ventrolateral PFC, as most studies have focused
on the amygdala. Surguladze and colleagues [34]
reported that the S/S group showed greater functional
connectivity between the right fusiform gyrus and the
right ventrolateral PFC in response to fearful faces.
Structural morphology of the ventrolateral PFC is asso-
ciated with emotion-cognition interaction in carriers of
the short allele of 5HTTLPR [70] who exhibit lower
5HT1A receptor density throughout the cortex [71]. In
tasks of social cognition, 5HTTLPR modulates ventro-
lateral PFC [72]. This evidence considered together with
increased ventrolateral activation in PTSD associated
with emotion-cognition studies [37,57,58] and conven-
tional symptom provocation studies [40,41,73] places
the ventrolateral PFC at the nexus between 5HTTLPR
and PTSD. Thus, increased vulnerability to PTSD and
other disorders associated with 5HTTLPR genotype may
be mediated through ventrolateral PFC engagement.
We find evidence at the trend level that 5-HTTLPR
differentially modulates left amygdala activation in S
allele carriers with PTSD. Specifically, S allele carriers
with PTSD tended toward greater left amygdala activa-
tion in response to combat (relative to non-combat) dis-
tractors presented during the working memory delay
period than trauma exposed controls. However this left
amygdala activation difference was not observed
between PTSD and trauma exposed control groups with
the LL genotype. This finding is related to three lines of
evidence showing that (i) 5-HTTLPR modulates threat-
related amygdala activity in healthy normal subjects
[28-35,74], (ii) heightened task-related amygdala activa-
tion in PTSD [37,38], and (iii) 5-HTTLPR may consti-
tute a vulnerability for developing PTSD in the setting
of trauma exposure [11]. Whereas initial reports in
healthy subjects showed a 5-HTTLPR effect only in the
right amygdala [30,31], subsequent reports extended this
finding to the left amygdala [28,33]. The overall balance
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demonstrate greater amygdala activation in PTSD com-
pared to controls [37,38,41,75-81]. These findings are
consistent with the amygdala playing a central role in
regulating responses to trauma reminders and cues [82].
Indeed, SLC6A4 has been implicated in PTSD, initially
with data from biallelic 5-HTTLPR [11], and in more
recent follow-up studies with triallelic 5-HTTLPR
[11-15]. However, the present results concerning the
role of 5-HTTLPR must be considered preliminary
given the paucity of S as well as L homozygote’si no u r
sample.
We did not observe the hypothesized association
between 5-HTTLPR and right amygdala activation as
previously reported in numerous imaging genetics inves-
tigations of healthy participants [28-34]. Several explana-
tions may account for this difference. First, our sample
contained the confounding effect of race. Second, the
behavioral task in most of the prior studies consisted of
viewing of fearful faces. This differs from the present
working memory task with trauma related distractors
that is designed to probe emotion-cognition interactions.
Third, previous studies included healthy individuals that
were not identified on the basis of trauma exposure and
the present study does not compare trauma-exposed
participants to healthy, non-exposed subjects. Finally,
the threat-related nature of the previous task stimuli
may elicit amygdala activation that has a unique associa-
tion with 5-HTTLPR that is not specific to our working
memory task where combat-related images are used as
distractors.
We did not find any associations with triallelic 5-
HTTLPR as might be suggested by several recent
reports of association to PTSD diagnosis in the setting
of high lifetime trauma exposure [11-15]. Our data was
limited in assessing the effects of triallelic 5-HTTLPR
on neural activity due to a lack of subjects possessing
the LALA gentoype. Reports of triallelic 5-HTTLPR gen-
erally show an interaction effect with the level of life-
time trauma exposure on diagnosis of PTSD whereas
the present study was designed to match for level of
trauma exposure between the PTSD and control group.
Moreover, we are not aware of studies showing effect of
triallelic 5-HTTLPR on brain function particularly as
further modulated by exposure to childhood trauma.
However in the overall group, we found increased left
and right amygdala activity and fusiform gyrus activity
associated with LALA. These findings are consistent with
results of emotion tasks eliciting greater amygdala acti-
vation that is differentially affected by the LALA geno-
type in a normative sample [83] and in major
depression [29].
While early imaging genetics studies of 5-HTTLPR
assessed only amygdala activity, some recent studies in
healthy subjects utilized cognitive attention and emo-
tion processing tasks to show not just modulatation of
amygdala, but also frontal cortical activation including
the anterior cingulate, dorsolateral PFC, intraparietal
sulcus, insula, and other regions [28,84]. We extend
these findings by showing that rs16965628, the first
tagging SNP downstream of 5-HTTLPR, modulates
task ventrolateral PFC activation in PTSD associated
with maintaining information in working memory
while being distracted by combat pictures. Our find-
ings support the supposition that fMRI data provides
us with an intermediate phenotype that is closer to the
function of proteins expressed by the candidate gene
than a clinical entity. Thus, the definition of a precise
intermediate phenotype that is closely linked to the
biological function of gene expression is imperative.
Core features of PTSD include hypervigilance and re-
experiencing symptoms associated with the processing
of emotional cues likely to be irrelevant to ongoing
task demands, resulting in distractibility and compro-
mised task performance. Emotional stimuli are known
to influence behavioral performance on experimental
tasks requiring cognitive processing [42,44-47], and
therefore brain systems mediating cognitive control of
emotion are relevant to PTSD [85]. While imaging
phenotypes may be closer to the action of genes com-
pared to behavioral or clinical phenotypes, it is certain
that the imaging phenotypes employed in the present
study are imprecise and are downstream manifestations
of multiple gene systems working together to produce
a complex ensemble of brain activity [27].
Based on preliminary nature of our results, the role of
rs16965628 in PTSD deserves further investigation.
While this SNP has not previously been described in
association with PTSD, nor does data from our sample
support an association of this SNP with PTSD as a diag-
nostic phenotype, there is currently insufficient informa-
tion available to characterize the role of this SNP in
PTSD or other anxiety disorders. Given the previous
association of 5-HTTLPR with PTSD, a role for
rs169656258 as a modifier is consistent with a number
of other disorders, most notably cystic fibrosis, a mono-
genic disease determined by mutations of the cystic
fibrosis transmembrane conductance regulator (CFTR)
gene [86]. In cystic fibrosis, other genes are required to
explain the clinical heterogeneity with the extent of liver
[87] and lung [88] involvement not explained by CFTR
alone. Conceived as a modifier SNP, the present results
suggest that rs16965628 predicts brain activity related to
the disruption of cognitive control by emotional or trau-
matic information in the ventrolateral prefrontal cortex.
This type of model is certainly one that deserves to be
investigated in PTSD where it is likely that multiple
genes might predict onset of PTSD and other genes or
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ity of PTSD in concert with environmental exposures
such as lifetime trauma.
It is important to consider the present findings in the
broader context of neuroimaging and genetics findings
observed in related neuropsychiatric disorders, particu-
larly major depression and anxiety disorders. There is
increasing evidence that a common set of underlying
mechanisms are operating in depression and PTSD that
may explain their shared diathesis [89]. Recent meta-
analyses showed consistent patterns of amygdala hyper-
activation in major depression [90], social phobia, speci-
fic phobia, and PTSD [91]. However, PTSD shows
divergent findings when compared to the other anxiety
disorders in the rostral anterior cingulate and ventral
and dorsal medial prefrontal regions [91]. In these
regions specific phobia and social phobia fail to show
differences, while the PTSD literature contains evidence
of both greater activation [[76], Lanius, 2002 #1016,
Morey, 2008 #625, Pannu Hayes, 2009 #654] and lower
activation [[92], Shin, 2005 #741, Bremner, 1999 #291,
[93]] in ventromedial prefrontal cortex, which may be
influenced by a variety of factors including illness
chronicity, emotional versus trauma-specific stimuli, and
others. Differences in ventrolateral PFC activity have
been consistently demonstrated in both PTSD and
depression. A meta-analysis of neuroimaging studies
using emotional stimuli in depression found increased
inferior frontal gyrus and left amygdala activation in
response to negative emotional images [94].
Similarly, genetic evidence supports a shared diathesis
for PTSD and depression. In 6,744 members of the Viet-
nam Era Twin Registry, major depression and PTSD
showed a large genetic correlation (r = .77; 95% CI) and
a modest individual-specific environmental correlation
(r = .34; 95% CI) [95]. In addition, genetic influences
common to depression explained 58% of the genetic
variance in PTSD but only 15% of the total variance in
r i s kf o rP T S D[ 9 5 ] .I n d i v i d u a l-specific environmental
influences common to depression explained only 11% of
the variance in PTSD [95]. These data do not examine
specific genetic loci nor the functional brain effects but
are nevertheless suggestive of a shared pretrauma
vulnerability.
Limitations
Several limitations pose caveats to the interpretation of
our results and warrant further investigation. Above all,
despite the correction for multiple comparisons, the
small sample size raises the possibility of Type I error.
In general, our case-control design is susceptible to
population stratification resulting from roughly equal
samples of European American and African American
ancestry with the latter having admixture from other
races. We addressed this issue by verifying a lack of a
race effect in the dependent variable and further by cov-
arying for race in all statistical modeling. However, spur-
ious associations can only be ruled out definitively by
ascertaining a racially homogenous sample, increasing
the sample size to permit separate analyses for both
racial groups, or through the inclusion of a large num-
ber of ancestry informative markers in the analysis.
Munafo and colleagues [35] have suggested minimum
sample size on N = 70 for imaging genetics studies
detecting 5HTTLPR effects. A much larger sample
would also allow haplotype analyses of rs16965628 with
5-HTTLPR and other common polymorphisms, and
consideration of epistatic effects. This would enable
further analysis of polymorphisms in LD with
rs16965628 including 5-HTTLPR and others that may
be the major functional locus or loci. In spite of these
limitations, we demonstrated reasonably robust effects
perhaps because the imaging phenotype is closer to the
effect of gene action than a behaviorally assessed clinical
phenotype.
It is also possible that many of the effects that were
significant at an uncorrected alpha level, but failed to
reach the corrected significance level, might constitute
Type II error resulting from the fairly small sample size.
We attempted to match PTSD and control groups for
level of trauma exposure, and a larger sample size and
more sophisticated design would offer the ability to
investigate whether gene-environment interactions
(GxE) demonstrated on behavioral phenotypes may be
detected on imaging phenotypes [51]. Gene effects may
be better assessed by incorporating differences in envir-
onment and lifetime trauma exposure that interact to
modulate gene expression as reflected by functional
brain differences. Environmental and genetic modifiers
have been studied in behavioral and psychiatric genetics
studies of traumatic stress and PTSD [12,15,16,96], but
GxE remains to be investigated in imaging genetics stu-
dies of PTSD where it could provide a window into
functional brain differences and neuroplasticity that are
modulated by the interaction of environmental and
genetic factors.
Conclusion
The SLC6A4 SNP rs16965628 and 5-HTTLPR are asso-
ciated with a bias in neural circuit responses to trau-
matic reminders and cognitive control of emotions in
patients with PTSD. Functional MRI may highlight
dimensions of PTSD that are more closely related to
susceptibility genes than current clinical categorizations,
which are subjectively measured and rely on diagnostic
criteria that are currently undergoing revision [97]. Neu-
roimaging may hold unique promise in highlighting spe-
cific functional brain differences as intermediate
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disease phenotypes. Associations found with imaging
genetics may guide further exploration and confirmation
using conventional candidate gene associations with
clinically defined phenotypes of PTSD.
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